Abbott Laboratories  

(Public, NYSE:ABT)   Watch this stock  
Find more results for Neisseria
36.21
-1.30 (-3.47%)
After Hours: 36.21 0.00 (0.00%)
Jun 19, 6:17PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 36.21 - 37.27
52 week 31.64 - 72.47
Open 37.27
Vol / Avg. 6.74M/7.01M
Mkt cap 56.45B
P/E 74.04
Div/yield 0.14/1.55
EPS 0.49
Shares 1.56B
Beta 0.22
Inst. own 67%
Jun 19, 2013
Abbott at Wells Fargo Health Care Conference - Webcast
Jun 11, 2013
Abbott at William Blair Growth Stock Conference - Webcast
Jun 11, 2013
Abbott at Goldman Sachs Healthcare Conference - Webcast
May 29, 2013
Abbott at EBD Group ChinaBio Partnering Forum
May 29, 2013
Abbott at 38th Annual dbAccess Health Care Conference - Webcast
May 22, 2013
Abbott at UBS Global Healthcare Conference - Webcast
Apr 26, 2013
Abbott Annual Shareholder Meeting
Apr 17, 2013
Q1 2013 Abbott Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 10.13% 2.69%
Operating margin 11.43% 1.64%
EBITD margin - 9.94%
Return on average assets 3.97% 0.91%
Return on average equity 8.86% 2.26%
Employees 91,000 -
Carbon Disclosure Rating - 80/100

Address

C/O TAX DEPT D367 & AP6D 100 Abbott Park Road
ABBOTT PARK, IL 60064-3500
United States - Map
+1-847-9376100 (Phone)
+1-847-9371511 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia
Discussion Group - Google Finance

Description

Abbott Laboratories (Abbott), is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company.

Officers and directors

Miles D. White Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Thomas C. Freyman Chief Financial Officer, Executive Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
Hubert L. Allen Executive Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Richard W. Ashley MBA Executive Vice President - Corporate Development
Age: 69
Bio & Compensation  - Reuters
Brian J. Blaser MBA Executive Vice President - Diagnostics Products
Age: 48
Bio & Compensation  - Reuters
John M. Capek Ph.D. Executive Vice President - Medical Devices
Age: 51
Bio & Compensation  - Reuters
Michael J. Warmuth MBA Executive Vice President - Established Pharmaceuticals
Age: 50
Bio & Compensation  - Reuters
Paul K. Magill Senior Vice President, Chief Marketing Officer
Age: 51
Bio & Compensation  - Reuters
Stephen R. Fussell Senior Vice President - Human Resources
Age: 55
Bio & Compensation  - Reuters
A. David Forrest Senior Vice President - International Nutrition
Age: 51
Bio & Compensation  - Reuters